EU
Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma
January 23, 2018Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma
Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …
European biotechs outperform US for investment return, report claims
November 29, 2017Medical Communications, Sales and Marketing EU, Europe, US, investment, pharma
A new report from RSA Group has revealed that European biotech companies are “significantly outperforming” their US counterparts in terms …
Boehringer celebrates EU approval of Humira biosimilar
November 14, 2017Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …
Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer
September 27, 2017Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq
It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …
Novartis scores EU approval in acute myeloid leukaemia and advanced systemic mastocytosis
September 20, 2017Research and Development, Sales and Marketing EU, Europe, Novartis, acute myeloid leukaemia, advanced systemic mastocytosis, pharma, pharmaceutical
Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications: newly …
Leo Pharma gets European approval for unique plaque psoriasis drug
July 20, 2017Sales and Marketing EU, European Commission, biotech, drugs, pharma, pharmaceutical, psoriasis
The European Commission has announced that it has decided to approve Leo Pharma’s Kyntheum (brodalumab), making it the first and …
What pharma should know about the European Unitary Patent in light of Brexit
July 17, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, UK, biotech, brexit, drugs, healthcare, pharma, pharmaceutical
The departure of the United Kingdom from the European Union, dubbed “Brexit,” has sparked significant economic global uncertainty. Two Brexit-related …
UK and EU life sciences demand closer collaboration in joint letter to Brexit negotiators
July 13, 2017Sales and Marketing EU, UK, biotech, brexit, drugs, life sciences, pharma, pharmacuetical
The pharmaceutical and life sciences industries have stressed the importance of cooperation between the EU and the UK in order …
New Pfizer EU approval offers first treatment option for leukaemia subtype
July 3, 2017Sales and Marketing AstraZeneca, Besponsa, EU, European Commission
Pfizer has revealed that its drug Besponsa (inotuzumab ozogamicin) has received approval from the European Commission as a monotherapy for …
Novo Nordisk’s diabetes drug recommended for expanded indication in Europe
June 27, 2017Research and Development, Sales and Marketing CHMP, EMA, EU, Novo Nordisk, Victoza
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to expand the indication of Novo …
PrimeVigilance is committed to minimising the impact of UK’s Withdrawal from the EU
June 14, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, brexit, primevigilance
Guildford, UK 14th June, 2017
New game, new rules: Pathways for better and affordable medicines in Europe
June 5, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, brexit, market access
Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines at the European Public Health Alliance (EPHA), discusses the latest …
AZ’s Tagrisso continues successes with EU approval
April 26, 2017Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso
More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …
Trials and Tribulations: The impact of new clinical trial regulation in Europe
April 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, UK, brexit, clinical trials, regulations
The clinical trial is the fulcrum on which drug development and treatment hinges. Even with the advent of new technologies …
Looming Brexit sparks fears for child cancer trials, experts warn
March 9, 2017Medical Communications, Research and Development EU, ICR, brexit
The trials of cancer treatments in the EU are already at a low level and Brexit has experts worried that …
Latest content
Five Facts about cardiovascular disease
